OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
2.390
+0.130 (5.75%)
At close: Aug 29, 2025, 4:00 PM
2.330
-0.060 (-2.51%)
After-hours: Aug 29, 2025, 6:46 PM EDT

Company Description

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.

Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.

OS Therapies Incorporated
OS Therapies logo
CountryUnited States
Founded2018
IPO DateAug 1, 2024
IndustryBiotechnology
SectorHealthcare
Employees5
CEOPaul Romness

Contact Details

Address:
115 Pullman Crossing Road, Suite 103
Grasonville, Maryland 21638
United States
Phone410-297-7793
Websiteostherapies.com

Stock Details

Ticker SymbolOSTX
ExchangeNYSEAMERICAN
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$4.00
CIK Code0001795091
ISIN NumberUS68764Y2072
Employer ID82-5118368
SIC Code2834

Key Executives

NamePosition
Paul A. Romness M.P.H.Founder, Chairman, President and Chief Executive Officer
Christopher P. AcevedoChief Financial Officer
Jack DollChief of Staff
Gerald E. CommissiongChief Business Officer

Latest SEC Filings

DateTypeTitle
Aug 26, 20258-KCurrent Report
Aug 26, 2025ARSFiling
Aug 25, 2025EFFECTNotice of Effectiveness
Aug 25, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Aug 25, 2025DEF 14AOther definitive proxy statements
Aug 25, 2025424B5Filing
Aug 25, 2025424B3Prospectus
Aug 19, 20258-KCurrent Report
Aug 18, 2025SCHEDULE 13D/AFiling
Aug 18, 202510-QQuarterly Report